Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.22
GLAXF's Cash to Debt is ranked higher than
52% of the 909 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.55 vs. GLAXF: 0.22 )
GLAXF' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.22

Equity to Asset 0.13
GLAXF's Equity to Asset is ranked lower than
54% of the 790 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. GLAXF: 0.13 )
GLAXF' s 10-Year Equity to Asset Range
Min: 0.05   Max: 0.4
Current: 0.13

0.05
0.4
Interest Coverage 9.68
GLAXF's Interest Coverage is ranked higher than
58% of the 555 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 203.80 vs. GLAXF: 9.68 )
GLAXF' s 10-Year Interest Coverage Range
Min: 0.81   Max: 28.06
Current: 9.68

0.81
28.06
F-Score: 6
Z-Score: 2.20
M-Score: -2.50
WACC vs ROIC
6.33%
22.47%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 22.54
GLAXF's Operating margin (%) is ranked higher than
92% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.33 vs. GLAXF: 22.54 )
GLAXF' s 10-Year Operating margin (%) Range
Min: 1.68   Max: 36.94
Current: 22.54

1.68
36.94
Net-margin (%) 17.63
GLAXF's Net-margin (%) is ranked higher than
91% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.06 vs. GLAXF: 17.63 )
GLAXF' s 10-Year Net-margin (%) Range
Min: 5.76   Max: 23.94
Current: 17.63

5.76
23.94
ROE (%) 68.04
GLAXF's ROE (%) is ranked higher than
99% of the 879 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. GLAXF: 68.04 )
GLAXF' s 10-Year ROE (%) Range
Min: 17.3   Max: 244.21
Current: 68.04

17.3
244.21
ROA (%) 10.35
GLAXF's ROA (%) is ranked higher than
91% of the 912 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.12 vs. GLAXF: 10.35 )
GLAXF' s 10-Year ROA (%) Range
Min: 3.84   Max: 26.32
Current: 10.35

3.84
26.32
ROC (Joel Greenblatt) (%) 58.14
GLAXF's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 907 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.05 vs. GLAXF: 58.14 )
GLAXF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.5   Max: 141.62
Current: 58.14

4.5
141.62
Revenue Growth (3Y)(%) -0.90
GLAXF's Revenue Growth (3Y)(%) is ranked higher than
62% of the 706 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.30 vs. GLAXF: -0.90 )
GLAXF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -1.5   Max: 15.3
Current: -0.9

-1.5
15.3
EBITDA Growth (3Y)(%) 17.30
GLAXF's EBITDA Growth (3Y)(%) is ranked higher than
82% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. GLAXF: 17.30 )
GLAXF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -11.8   Max: 17.3
Current: 17.3

-11.8
17.3
EPS Growth (3Y)(%) 51.40
GLAXF's EPS Growth (3Y)(%) is ranked higher than
94% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. GLAXF: 51.40 )
GLAXF' s 10-Year EPS Growth (3Y)(%) Range
Min: -30.2   Max: 51.4
Current: 51.4

-30.2
51.4
» GLAXF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GLAXF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 17.10
GLAXF's P/E(ttm) is ranked higher than
93% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 51.10 vs. GLAXF: 17.10 )
GLAXF' s 10-Year P/E(ttm) Range
Min: 10.16   Max: 40.41
Current: 17.1

10.16
40.41
Forward P/E 15.17
GLAXF's Forward P/E is ranked higher than
92% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 60.61 vs. GLAXF: 15.17 )
N/A
PE(NRI) 17.30
GLAXF's PE(NRI) is ranked higher than
92% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 51.10 vs. GLAXF: 17.30 )
GLAXF' s 10-Year PE(NRI) Range
Min: 10.17   Max: 41.19
Current: 17.3

10.17
41.19
P/B 13.97
GLAXF's P/B is ranked higher than
53% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.81 vs. GLAXF: 13.97 )
GLAXF' s 10-Year P/B Range
Min: 5.48   Max: 14.29
Current: 13.97

5.48
14.29
P/S 3.02
GLAXF's P/S is ranked higher than
77% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.97 vs. GLAXF: 3.02 )
GLAXF' s 10-Year P/S Range
Min: 1.94   Max: 4.89
Current: 3.02

1.94
4.89
PFCF 20.38
GLAXF's PFCF is ranked higher than
94% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. GLAXF: 20.38 )
GLAXF' s 10-Year PFCF Range
Min: 8.21   Max: 41.33
Current: 20.38

8.21
41.33
POCF 13.84
GLAXF's POCF is ranked higher than
91% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 39.14 vs. GLAXF: 13.84 )
GLAXF' s 10-Year POCF Range
Min: 6.64   Max: 22.97
Current: 13.84

6.64
22.97
EV-to-EBIT 16.08
GLAXF's EV-to-EBIT is ranked higher than
88% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.50 vs. GLAXF: 16.08 )
GLAXF' s 10-Year EV-to-EBIT Range
Min: 7.7   Max: 240.2
Current: 16.08

7.7
240.2
PEG 6.65
GLAXF's PEG is ranked higher than
86% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. GLAXF: 6.65 )
GLAXF' s 10-Year PEG Range
Min: 0.3   Max: 99.36
Current: 6.65

0.3
99.36
Shiller P/E 16.88
GLAXF's Shiller P/E is ranked higher than
95% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 229.54 vs. GLAXF: 16.88 )
GLAXF' s 10-Year Shiller P/E Range
Min: 10.93   Max: 21.15
Current: 16.88

10.93
21.15
Current Ratio 0.97
GLAXF's Current Ratio is ranked lower than
52% of the 862 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.41 vs. GLAXF: 0.97 )
GLAXF' s 10-Year Current Ratio Range
Min: 0.97   Max: 1.78
Current: 0.97

0.97
1.78
Quick Ratio 0.69
GLAXF's Quick Ratio is ranked lower than
52% of the 862 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. GLAXF: 0.69 )
GLAXF' s 10-Year Quick Ratio Range
Min: 0.68   Max: 1.42
Current: 0.69

0.68
1.42
Days Inventory 191.79
GLAXF's Days Inventory is ranked higher than
64% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 149.40 vs. GLAXF: 191.79 )
GLAXF' s 10-Year Days Inventory Range
Min: 145.16   Max: 321.53
Current: 191.79

145.16
321.53
Days Sales Outstanding 79.77
GLAXF's Days Sales Outstanding is ranked higher than
75% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 86.21 vs. GLAXF: 79.77 )
GLAXF' s 10-Year Days Sales Outstanding Range
Min: 54.62   Max: 114.48
Current: 79.77

54.62
114.48

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 5.90
GLAXF's Dividend Yield is ranked higher than
98% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.32 vs. GLAXF: 5.90 )
GLAXF' s 10-Year Dividend Yield Range
Min: 2.72   Max: 5.91
Current: 5.9

2.72
5.91
Dividend Payout 0.93
GLAXF's Dividend Payout is ranked higher than
99% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.63 vs. GLAXF: 0.93 )
GLAXF' s 10-Year Dividend Payout Range
Min: 0.38   Max: 4.69
Current: 0.93

0.38
4.69
Dividend growth (3y) 6.40
GLAXF's Dividend growth (3y) is ranked higher than
79% of the 340 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. GLAXF: 6.40 )
GLAXF' s 10-Year Dividend growth (3y) Range
Min: -12.6   Max: 20.8
Current: 6.4

-12.6
20.8
Yield on cost (5-Year) 8.08
GLAXF's Yield on cost (5-Year) is ranked higher than
97% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.44 vs. GLAXF: 8.08 )
GLAXF' s 10-Year Yield on cost (5-Year) Range
Min: 3.73   Max: 8.1
Current: 8.08

3.73
8.1
Share Buyback Rate 1.40
GLAXF's Share Buyback Rate is ranked higher than
90% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.10 vs. GLAXF: 1.40 )
GLAXF' s 10-Year Share Buyback Rate Range
Min: 3.6   Max: -20
Current: 1.4

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.50
GLAXF's Price/DCF (Projected) is ranked higher than
91% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.94 vs. GLAXF: 1.50 )
GLAXF' s 10-Year Price/DCF (Projected) Range
Min: 0.82   Max: 21.79
Current: 1.5

0.82
21.79
Price/Median PS Value 1.04
GLAXF's Price/Median PS Value is ranked higher than
83% of the 962 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.33 vs. GLAXF: 1.04 )
GLAXF' s 10-Year Price/Median PS Value Range
Min: 0.69   Max: 3.21
Current: 1.04

0.69
3.21
Earnings Yield (Greenblatt) 6.20
GLAXF's Earnings Yield (Greenblatt) is ranked higher than
88% of the 907 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. GLAXF: 6.20 )
GLAXF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 12.9
Current: 6.2

0.4
12.9
Forward Rate of Return (Yacktman) 7.29
GLAXF's Forward Rate of Return (Yacktman) is ranked higher than
74% of the 500 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.48 vs. GLAXF: 7.29 )
GLAXF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4.1   Max: 53.2
Current: 7.29

4.1
53.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:JNJ, PFE, RHHBY, NVS, ABT » details
Traded in other countries:GSK.UK, GSK.USA, GS7A.Germany, GS7.Germany, GSK N.Mexico, GSK.Argentina, GSK.Switzerland,
GlaxoSmithKline PLC incorporated in United Kingdom. The Company creates, discoveres, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and HIV. The Company is a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare. Its Pharmaceuticals business develops and makes medicines to treat a broad range of acute and chronic diseases. Its portfolio is made up of both patent-protected and off patent medicines. Its products include treatment for Infectious Diseases, Cancer, Epilepsy, Heart Disease, Asthma and Chronic obstructive pulmonary disease, and HIV/AIDS. Its Vaccine business has approximately 900 million doses distributed to 170 countries in 2012. It produces paediatric and adult vaccines to prevent a range of infectious diseases including: Hepatitis A and B, Diphtheria, Tetanus and Whooping cough, Measles, Mumps and Rubella, Polio, Typhoid, Influenza, Bacterial Meningitis. The consumer healthcare business, markets consumer health products based on scientific innovation. Its products main categories are: Oral care, Nutritional, Total wellness, and Skin health. Its barands include Sensodyne, Panadol and Horlicks. Its drinks brands are Lucozade and Ribena. The Oral Care brands, alli and Abreva.
» More Articles for GLAXF

Headlines

Articles On GuruFocus.com
Can GlaxoSmithKline Continue Striving in the Face of World Challenges? Jan 30 2015 
Tumor Drug Takes The Focus At OncoMed Pharmaceuticals Jan 29 2015 
Gilead Sciences Still has More Upside Jan 22 2015 
Johnson & Johnson Riding High On Ebola Vaccines Jan 21 2015 
set Jan 11 2015 
tester Dec 18 2014 
Weekly 3-Year Low Highlights: RDS.B, GSK, WPZ, CLR Dec 14 2014 
Pfizer Spreading Its Wings Into A New Domain Of Life Sciences Dec 09 2014 
The Top 5 European Stocks Held During Q3 Nov 25 2014 
Jeff Auxier Buys Berkshire Hathaway in Third Quarter Nov 18 2014 

More From Other Websites
Cross Section of a Revolution, Lisson Gallery, London Jan 30 2015
Ebola's worst enemy: disease control expert Dr Anthony S Fauci Jan 30 2015
Does it matter that an entire generation of bankers has disappeared? Jan 29 2015
EU puts conditions on deals involving Novartis, GSK Jan 28 2015
EU clears plans by drugmakers GSK and Novartis to trade assets Jan 28 2015
EU clears GSK's acquisition of Novartis vaccines with conditions Jan 28 2015
EU clears GSK's acquisition of Novartis vaccines with conditions Jan 28 2015
Novartis profits jump 12% on new drug sales Jan 27 2015
Novartis looks to new drugs to fuel growth as restructuring gels Jan 27 2015
Currency market swings hit global effort to fund vaccinations Jan 26 2015
Vodafone payout helps dividends hit £97bn record Jan 25 2015
WHO says cash crunch, rains could thwart Ebola efforts Jan 23 2015
Ebola: British drug company ships experimental vaccine to Liberia Jan 23 2015
GSK ships Ebola vaccine to west Africa Jan 23 2015
US health officials say Ebola treatment trial to start soon in Liberia Jan 22 2015
Vaccines group seeks $7.5 bln as disease fight reaches peak Jan 22 2015
Hungry Actavis pauses to digest Allergan Jan 21 2015
Self-doubt in snow boots: the reality of Davos for most CEOs Jan 19 2015
Sacking the boss is no panacea for a shrivelling stock price Jan 18 2015
GSK's nicotine patches and gum feel the heat from e-cigarettes Jan 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK